Last reviewed · How we verify
SAL-0951 tablets
SAL-0951 tablets is a SGLT2 inhibitor Small molecule drug developed by Shenzhen Salubris Pharmaceuticals Co., Ltd.. It is currently in Phase 3 development for Type 2 diabetes, Chronic kidney disease. Also known as: SAL-0951 group.
SAL-0951 tablets are a small molecule drug that targets the SGLT2 receptor.
SAL-0951 tablets are being studied in clinical trials for the treatment of Anemia and Renal Anemia in Non-dialysis Chronic Kidney Disease. The exact mechanism of SAL-0951 tablets is not specified in the provided facts, but it is being investigated in a Phase II clinical study.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SAL-0951 tablets |
|---|---|
| Also known as | SAL-0951 group |
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SAL-0951 tablets work by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, SAL-0951 tablets also have a mild diuretic effect, which can help to reduce blood pressure.
Approved indications
- Type 2 diabetes
- Chronic kidney disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies (PHASE2)
- Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis (PHASE3)
- Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis (PHASE3)
- SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAL-0951 tablets CI brief — competitive landscape report
- SAL-0951 tablets updates RSS · CI watch RSS
- Shenzhen Salubris Pharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about SAL-0951 tablets
What is SAL-0951 tablets?
How does SAL-0951 tablets work?
What is SAL-0951 tablets used for?
Who makes SAL-0951 tablets?
Is SAL-0951 tablets also known as anything else?
What drug class is SAL-0951 tablets in?
What development phase is SAL-0951 tablets in?
What are the side effects of SAL-0951 tablets?
What does SAL-0951 tablets target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: Shenzhen Salubris Pharmaceuticals Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Indication: Drugs for Chronic kidney disease
- Also known as: SAL-0951 group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing